Form 4: Verona Pharma Director Sells Shares Amid Acquisition

Verona Pharma director Christina Ackermann reported the disposition of ordinary shares, restricted share units, and share options following a Scheme of Arrangement related to an acquisition by Merck Sharp & Dohme LLC.

Summary

• Christina Ackermann, a Director of Verona Pharma plc (VRNA), reported changes in her beneficial ownership of the company's securities.
• The transactions occurred on October 7, 2025, as a result of a Scheme of Arrangement under the UK Companies Act 2006, pursuant to a Transaction Agreement dated July 8, 2025.
• Verona Pharma plc was acquired by Merck Sharp & Dohme LLC and its wholly-owned subsidiary, Vol Holdings LLC.
• At the effective time of the Scheme of Arrangement, holders of Scheme Shares became entitled to receive $13.375 in cash per Ordinary Share.
• Holders of American Depositary Shares (ADSs), each representing eight Ordinary Shares, became entitled to receive $107 in cash per ADS.
• Ms. Ackermann disposed of 64,072 Ordinary Shares directly.
• She also exercised 72,000 Restricted Share Units (RSUs) which immediately vested and converted into the right to receive cash based on the ADS Consideration.
• Concurrently, 72,000 Ordinary Shares related to the RSU conversion were disposed of.
• Additionally, 200,000 Share Options with an exercise price of $1.9338 and 144,000 Share Options with an exercise price of $2.4288 became fully vested and converted into the right to receive cash, as their exercise prices were less than the ADS Consideration.

Sentiment

Score: 7

Explanation: The sentiment is positive for shareholders and equity award holders who received cash for their holdings, indicating a successful exit. However, it is neutral to slightly negative for those who might have wished for Verona Pharma to continue as an independent growth company, as it ceases to exist as such.

Positives

• Shareholders, including the reporting director, received a cash payout of $13.375 per Ordinary Share or $107 per ADS, indicating a successful acquisition for investors.
• Outstanding Restricted Share Units and Share Options held by the director became fully vested and converted into cash, providing liquidity and value realization for equity compensation.

Negatives

• Verona Pharma plc ceases to exist as an independent publicly traded entity following the acquisition, removing it from public investment opportunities.
• The director no longer holds beneficial ownership in Verona Pharma plc's ordinary shares or derivative securities, reflecting the company's acquisition.

Risks

• This Form 4 reports a completed transaction (acquisition), thus resolving the primary pre-acquisition risks for shareholders, such as the deal not closing or a lower acquisition price. No new specific risks for the acquired entity are detailed in this filing.

Future Outlook

This filing reports the completion of an acquisition, meaning Verona Pharma plc will no longer operate as an independent entity. Therefore, the filing does not provide a future outlook for the company's independent operations or strategic direction.

Industry Context

The acquisition of Verona Pharma plc by Merck Sharp & Dohme LLC reflects ongoing consolidation within the pharmaceutical industry, where larger players acquire companies with promising assets or pipelines to expand their portfolios. This transaction indicates strategic interest in Verona Pharma's therapeutic areas or intellectual property.

Comparison to Industry Standards

• The use of a Scheme of Arrangement under the UK Companies Act 2006 is a standard legal mechanism for corporate acquisitions involving UK-incorporated companies.
• Cash consideration for shares, RSUs, and in-the-money options is a common and straightforward method for structuring M&A transactions, providing immediate liquidity to shareholders and equity award holders.
• The acquisition by a major pharmaceutical company like Merck Sharp & Dohme is consistent with industry trends of strategic M&A to enhance product pipelines and market presence.

Corporate Governance

Stakeholder Impact

• Shareholders: Received a cash payout for their shares, realizing value from their investment.
• Equity Award Holders (e.g., Director Christina Ackermann): RSUs and Share Options vested and converted to cash, providing liquidity for their equity compensation.
• Employees: While not detailed in this filing, acquisitions typically lead to integration processes that can impact employee roles, benefits, and organizational structure.
• Customers and Suppliers: May experience changes in relationships or operational procedures as Verona Pharma integrates into Merck Sharp & Dohme LLC.

Next Steps

• The acquisition of Verona Pharma plc by Merck Sharp & Dohme LLC is complete, and the company is no longer an independent entity. No further actions for Verona Pharma as a standalone public company are expected.

Key Dates

Keywords

Verona Pharma, VRNA, Merck Sharp & Dohme, Acquisition, Form 4, Insider Transaction, Director, Share Options, Restricted Share Units, Scheme of Arrangement, Cash Payout